SCHEMBL31824

SCHEMBL31824

Cc1ccsc1C(=O)Nc1cc(CO)ccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 4/20 0.66
▸ AURKB Q96GD4 2/20 0.66
▸ NPC1 O15118 5/20 0.43
▸ RAB9A P51151 5/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ CASP3 P42574 2/20 0.38
▸ SENP8 Q96LD8 2/20 0.38
▸ SENP7 Q9BQF6 2/20 0.38
▸ SENP6 Q9GZR1 2/20 0.38
▸ FGFR1 P11362 2/20 0.37
▸ HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313957 1.00 AURKA (0.66) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4321138 0.92 AURKA (0.63) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4321146 0.92 AURKA (0.63) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL31854 0.92 AURKA (0.63) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4312994 0.91 AURKA (0.62) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL27691460 0.91 AURKA (0.62) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4312987 0.91 AURKA (0.62) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4327020 0.88 AURKA (0.58) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4327023 0.88 AURKA (0.58) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4313205 0.88 AURKA (0.74) AURKAAURKBNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP disclosed
WO-2012026511-A1 PHARMACEUTICAL COMPOSITION 協和発酵キリン株式会社 (JP) 2012-03-01 — — WO disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885NPC1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback